Related references
Note: Only part of the references are listed.Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration
Masayuki Hata et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2017)
Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration
Hideki Koizumi et al.
OPHTHALMOLOGY (2016)
TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION
Hidetaka Matsumoto et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy
Yong-Kyu Kim et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
Nadim Rayess et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
PACHYCHOROID NEOVASCULOPATHY
Claudine E. Pang et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2015)
Pachychoroid neovasculopathy and age-related macular degeneration
Masahiro Miyake et al.
SCIENTIFIC REPORTS (2015)
Comparison of Exudative Age-related Macular Degeneration Subtypes in Japanese and French Patients: Multicenter Diagnosis With Multimodal Imaging
Gabriel Coscas et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)
PACHYCHOROID PIGMENT EPITHELIOPATHY
David J. Warrow et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
Michael W. Stewart
BRITISH JOURNAL OF OPHTHALMOLOGY (2012)
Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results
Taizo Yamazaki et al.
OPHTHALMOLOGY (2012)
Subfoveal Retinal and Choroidal Thickness After Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Ichiro Maruko et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2011)
Combined Photodynamic Therapy With Verteporfin and Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Taku Sato et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2010)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
TREAT AND EXTEND DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION
Michael Engelbert et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
Napoleone Ferrara et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization
JP Tong et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2006)
Share Paper
